New Delhi, May 22 -- Jubilant Pharmova on Friday reported a 14 per cent rise YoY in revenue to Rs 8,280 crore for the financial year 2025-26, driven by strong growth across its key business segments including CDMO Sterile Injectables, Allergy Immunotherapy, Radiopharma and Generics.

The company in an official statement shared that EBITDA for FY26 increased by 8 per cent to Rs 1,326 crore, while normalised profit after tax (PAT) rose 7 per cent to Rs 442 crore.

The board has also proposed a dividend of Rs 5 per equity share. For the fourth quarter of FY26, revenue increased 19 per cent year-on-year to Rs 2,290 crore, while EBITDA rose 2 per cent to Rs 363 crore.

According to the company, the CDMO Sterile Injectables business emerged as ...